UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 14D-9
(Rule 14d-101)
Solicitation/Recommendation Statement
Under Section 14(d)(4) of the Securities
Exchange Act of 1934
POINT Biopharma Global Inc.
(Name of Subject Company)
POINT Biopharma Global Inc.
(Name of Persons Filing Statement)
Common Stock, par value $0.0001 per share
(Title of Class of Securities)
730541109
(CUSIP Number of Class of Securities)
Joe McCann
Chief Executive Officer
4850 West 78th Street,
Indianapolis, IN
(317) 543-9957
(Name, address, and telephone numbers of person
authorized to receive notices and communications
on behalf of the persons filing statement)
| With copies to: |
|
Graham Robinson
Chadé Severin
Skadden, Arps, Slate, Meagher & Flom
LLP
500 Boylston Street, 23rd Floor
Boston, Massachusetts 02116
(617) 573-4800
|
| x |
Check the box if the filing relates solely to preliminary communications
made before the commencement of a tender offer.
|
This Schedule 14D-9 filing relates solely to preliminary communications
made before the commencement of a planned tender offer (the “Offer”) by Yosemite Falls Acquisition Corporation (“Merger
Sub”), a Delaware corporation and a direct or indirect wholly owned subsidiary of Eli Lilly and Company (“Parent”),
for all of the outstanding shares of common stock, par value $0.0001 per share of POINT Biopharma Global Inc. (the “Company”),
to be commenced pursuant to the Agreement and Plan of Merger, dated as of October 2, 2023, among the Company, Parent and Merger Sub.
If successful, the Offer will be followed by a merger of Merger Sub with and into the Company (the “Merger”).
This Schedule 14D-9 filing consists of the following documents relating
to the proposed Offer and Merger:
Additional Information and Where to Find It
The Offer described in this communication has not yet commenced. This
communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any securities,
nor is it a substitute for the Offer materials that Parent and Merger Sub will file with the United States Securities and Exchange Commission
(the “SEC”) upon commencement of the Offer. A solicitation and offer to buy outstanding shares of the Company will only be
made pursuant to the Offer materials that Parent and Merger Sub intend to file with the SEC. At the time the Offer is commenced, Parent
and Merger Sub will file Offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule
14D-9 with the SEC with respect to the Offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND
CERTAIN OTHER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION
AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS
AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE OFFER.
The Offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation
Statement, will be made available to all stockholders of the Company at no expense to them at Parent’s website at investor.lilly.com
and (once they become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and
certain other offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to the information
agent for the Offer, which will be named in the tender offer materials. The information contained in, or that can be accessed through,
Parent’s website is not a part of, or incorporated by reference into, this communication. The Offer materials (including the Offer
to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available
for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain
other Offer documents, as well as the Solicitation/Recommendation Statement, Parent and the Company file annual, quarterly, and current
reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Parent
and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This Schedule 14D-9 contains forward-looking statements related to
the Company, Parent and the proposed transaction that involve substantial risks and uncertainties. Forward-looking statements include
any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”,
“goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue”
and similar expressions. In this Schedule 14D-9, the Company’s forward-looking statements include statements about the parties’
ability to satisfy the conditions to the consummation of the Offer and the other conditions to the consummation of the proposed transaction;
statements about the expected timetable for completing the proposed transaction; the Company’s plans, objectives, expectations and
intentions; the financial condition, results of operations and business of the Company and Parent; the ability to successfully commercialize
the Company’s product candidates and generate future revenues with respect to the Company’s product candidates; and the anticipated
timing of the closing of the proposed transaction.
Forward-looking statements are subject to certain risks, uncertainties
or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in any
such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to differ
from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the Offer
and the Merger; uncertainties as to how many of the Company’s stockholders will tender their shares in the Offer; the possibility
that competing offers will be made; the possibility that various closing conditions for the proposed transaction may not be satisfied
or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the proposed transaction;
the effects of the proposed transaction on relationships with employees, other business partners or governmental entities; the difficulty
of predicting the timing or outcome of U.S. Food and Drug Administration approvals or actions, if any; the impact of competitive products
and pricing; that Parent may not realize the potential benefits of the proposed transaction; other business effects, including the effects
of industry, economic or political conditions outside of the companies’ control; transaction costs; actual or contingent liabilities;
and other risks listed under the heading “Risk Factors” in the Company’s periodic reports filed with the U.S. Securities
and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K,
as well as the Schedule 14D-9 to be filed by the Company and the Schedule TO and related tender offer documents to be filed by Parent
and Merger Sub. You should not place undue reliance on these statements. All forward-looking statements are based on information currently
available to the Company and Parent, and the Company and Parent disclaim any obligation to update the information contained in this communication
as new information becomes available.
Exhibit 99.1
Email to employees
Dear Team,
A few moments ago, it was announced
(link to press release) that POINT Biopharma Global Inc. has entered into a definitive agreement to be acquired by Lilly, one
of the largest and most well-respected pharmaceutical companies in the world. As the news sinks in and the details are explained, I
hope that you will come to feel as excited about our next chapter as I am. We are now better positioned than ever to become a world leader
in next-generation radioligand therapies.
Lilly has been interested in new cancer
fighting platform technologies that can serve as the foundation for its oncology growth strategy, including radiopharmaceuticals. POINT’s
team, infrastructure and capabilities stood out as truly unique in the industry, and discussions led to today’s announcement.
This sale to Lilly was carefully considered
by our leadership team and Board of Directors with advice from external professionals. POINT will benefit from Lilly’s resources,
expertise and global reach to accelerate the discovery, development and global access to radiopharmaceuticals.
I’m sure that you will have many
questions about how this news impacts POINT as well as you personally. We will do everything we can to provide information as it becomes
available. To begin with, we will be hosting an All-Employees Town Hall this morning at 11am ET.
There will be many more opportunities
for you to ask questions ahead of the deal closing, which is expected to occur prior to the end of this year. In addition, I have
created an email address – questions@pointbiopharma.com – to which you can submit questions at any time, and either
myself or the appropriate person will respond. Finally, a member of Lilly’s Oncology team will be joining us at a future Town Hall,
and I know they look forward to speaking to you directly.
Thank you for all of your efforts. In
under four years, we have taken just an idea – that radioligand therapy can be a new pillar of cancer care – to reality.
In the future, patients all over the world can benefit from receiving new and innovative treatment options, which will only exist because
of all your work. For that, I am incredibly proud, and I thank you all for your past and future contributions to this amazing journey.
Thank you, and I look forward to celebrating with you all soon.
Sincerely,
Joe
For additional information, please
see announcement press release (link to press release).
Additional Information and Where
to Find It
The tender offer described in this communication
has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of
an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will
file with the United States Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. A solicitation
and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Lilly and its acquisition
subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender
offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER
OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS
AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER
OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation
Statement, will be made available to all stockholders of the Company at no expense to them at Lilly’s website at investor.lilly.com
and (once they become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and
certain other offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to
the information agent for the tender offer, which will be named in the tender offer materials. The information contained in, or that
can be accessed through, Lilly’s website is not a part of, or incorporated by reference into, this communication. The tender offer
materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement,
will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related
Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company
file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements
or other information filed by Lilly and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This communication contains forward-looking
statements related to the Company, Lilly and the proposed transaction that involve substantial risks and uncertainties. Forward-looking
statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,”
“seek,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue” and similar expressions. In this communication, the Company’s forward-looking statements include statements
about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation
of the proposed transaction; statements about the expected timetable for completing the proposed transaction; the Company’s plans,
objectives, expectations and intentions; the financial condition, results of operations and business of the Company and Lilly; the ability
to successfully commercialize the Company’s product candidates and generate future revenues with respect to the Company’s
product candidates; and the anticipated timing of the closing of the proposed transaction.
Forward-looking statements are subject
to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially
from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause
the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties
as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s stockholders will tender their
shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the
proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval
for the consummation of the proposed transaction; the effects of the proposed transaction on relationships with employees, other business
partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals
or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential benefits of the proposed
transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’
control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in
the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K,
quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by the Company and the
Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not place undue reliance
on these statements. All forward-looking statements are based on information currently available to the Company and Lilly, and the Company
and Lilly disclaim any obligation to update the information contained in this communication as new information becomes available.
Exhibit 99.2
Employee
FAQ
| 1. | What
was announced today? |
| · | Lilly
and POINT Biopharma Global Inc. (“POINT”) announced an agreement for the
acquisition of POINT for $12.50 per share, or approximately $1.4 billion. |
| 2. | Why
does Lilly want to acquire POINT? |
| · | Lilly
was looking for opportunities to expand the breadth of its oncology portfolio and recognized
POINT’s leadership in the discovery, development and global access to next-generation
radioligand therapies for cancer treatment, something which Lilly does not do today. |
| 3. | Will
POINT Biopharma continue to operate independently as a wholly owned subsidiary of Lilly?
How will this transaction impact POINT employees? |
| · | Integration
planning is in process. That said, it is very important to leadership and our Board that
all of POINT’s employees are treated well in this transition. For the time being, we
need to do our best to remain focused on our day-to-day work, keeping in mind the same patient
focus that has driven everything we have done to date. Remember, a key reason for the acquisition
of POINT was to acquire the teams that made POINT what it is today. |
| 4. | When
will we receive more information on timelines and integration plans? |
| · | Integration
planning is in process, and we expect further clarity in the coming weeks. |
| 5. | Does
Lilly have operations in Canada? Will I need to relocate, or work out of Lilly’s offices? |
| · | Lilly
does have offices in Canada, and many employees of Loxo@Lilly, part of Lilly’s oncology
division, work remotely. POINT will continue to operate as a hybrid remote/in-office company,
in Canada and the United States. |
| 6. | What
happens with our benefits following the deal close? |
| · | Integration
planning is in process. Although no changes to benefits are currently contemplated, we expect
further clarity over the coming weeks. |
| 7. | What
will happen to my stock options? |
| · | All
current POINT stock options will be fully (100%) vested at the closing of the transaction
and option holders will generally be cashed out in the transaction. This generally means
that, shortly following the closing of the transaction, option holders will receive in cash
the purchase price of $12.50 per share less the stock option exercise price per share, tax
withholdings and required deductions for each option share held. Employees will not be required
to purchase their option shares by a cash payment. Certain Canadian option holders will be
subject to a separate process. More specifics on this process will be provided in the coming
weeks. Please consult your tax advisor to address your personal situation. |
| 8. | Will
we receive our full 2023 bonuses? |
| · | Every
employee of POINT will receive 100% of your target 2023 short term incentive bonus payment,
subject to your continued employment through the remainder of 2023 and until the payment
date, which we expect further clarity over the coming weeks. |
| 9. | But
as an employee who joined POINT after October 1st, 2022, I have not
yet received any Long-Term Incentive (LTI) grants? |
| · | Employees
who joined POINT between October 1st, 2022, and August 31st,
2023, who have yet to be granted stock options will receive a special cash payment at closing,
subject to your continued employment. We expect further clarity over the coming weeks. |
| 10. | When
will the tender offer and transaction become final? |
| · | We
currently anticipate that the tender offer and acquisition will be completed prior to the
end of this year, subject to the satisfaction or waiver of customary closing conditions,
including the tender of a majority of the outstanding shares of POINT’s common stock.
In addition, the U.S. Nuclear Regulatory Commission is required to approve the transfer of
some of POINT’s licenses. |
| 11. | What
happens between now and close? |
| · | Between
the signing and closing, POINT and Lilly remain separate independent companies and POINT
will continue to run its business as usual. Under federal law, POINT and Lilly are restricted
from engaging in joint operations until the transaction has been completed. We may need to
discuss certain exceptional or unusual commitments, but it is basically business as usual. |
| 12. | What
happens to our agreement with Lantheus? |
| · | Our
agreement with Lantheus is not impacted by today’s announcement. Lantheus continues
to remain the commercialization partner for both PNT2002 and PNT2003 with POINT providing
commercial supply. All joint steering committees and activities will continue as planned. |
| 13. | What
changes will be made to the current POINT organizational structure or corporate goals? |
| · | Integration
planning is in process, and we expect further clarity in the coming weeks. We will continue
to be focused on our 2023 corporate goals and deliverables, just as we were as an independent
company, and POINT will continue to run its business as usual. |
| 14. | When
will more information about the transaction and the background to the transaction be available? |
| · | Lilly
will initiate the tender offer process with a public filing of a tender offer document, and
POINT will make its own public filing at the same time. Please review these documents for
additional information about the transaction and the background to the transaction. |
| 15. | When
will we receive more information on the timelines and integration plans? |
| · | We
will work with Lilly to plan more detailed communications. While many details will be shared
immediately following the closing, we will share updates (as appropriate) in the coming weeks. |
For
additional information, please see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma
Additional
Information and Where to Find It
The
tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither
an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that
Lilly and its acquisition subsidiary will file with the United States Securities and Exchange Commission (the “SEC”) upon
commencement of the tender offer. A solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the
tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced,
Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED
LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE
DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING
THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter
of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of the Company at no
expense to them at Lilly’s website at investor.lilly.com and (once they become available) will be mailed to the stockholders of
the Company free of charge. Free copies of these materials and certain other offering documents will be made available by the Company
by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN 46268, Attention: Investor Relations, by email
at investors@pointbiopharma.com, or by directing requests for such materials to the information agent for the tender offer, which
will be named in the tender offer materials. The information contained in, or that can be accessed through, Lilly’s website is
not a part of, or incorporated by reference into, this communication. The tender offer materials (including the Offer to Purchase and
the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the
SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other
tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company file annual, quarterly, and current
reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly
and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward
Looking Statements
This
communication contains forward-looking statements related to the Company, Lilly and the proposed transaction that involve substantial
risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,”
“predict,” “project,” “seek,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue” and similar expressions. In this communication,
the Company’s forward-looking statements include statements about the parties’ ability to satisfy the conditions to the consummation
of the tender offer and the other conditions to the consummation of the proposed transaction; statements about the expected timetable
for completing the proposed transaction; the Company’s plans, objectives, expectations and intentions; the financial condition,
results of operations and business of the Company and Lilly; the ability to successfully commercialize the Company’s product candidates
and generate future revenues with respect to the Company’s product candidates; and the anticipated timing of the closing of the
proposed transaction.
Forward-looking
statements are subject to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or
results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and
uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among
other things: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s
stockholders will tender their shares in the tender offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the proposed transaction; the effects of the proposed transaction on relationships
with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and
Drug Administration approvals or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential
benefits of the proposed transaction; other business effects, including the effects of industry, economic or political conditions outside
of the companies’ control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk
Factors” in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports
on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by
the Company and the Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not
place undue reliance on these statements. All forward-looking statements are based on information currently available to the Company
and Lilly, and the Company and Lilly disclaim any obligation to update the information contained in this communication as new information
becomes available.
Exhibit 99.3
Investor
FAQ
| 1. | When
will more information about the transaction and negotiations be available? |
| · | Lilly
will initiate the tender offer process with a public filing of a tender offer document, and
POINT Biopharma Global Inc. (“POINT”) will make its own public filing at the
same time. Please review these documents for additional background to the transaction. |
| · | Our
Board has determined that this transaction is in the best interests of the company and its
shareholders. Further information will be set forth in the tender offer documents to be filed
with the SEC. |
| 3. | What
will happen with the structure of the company? |
| · | Integration
plans have not yet been finalized. |
| 4. | What
happens between now and close? |
| · | POINT
will continue to operate as an independent entity. |
For
additional information, please see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma
Additional
Information and Where to Find It
The
tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither
an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that
Lilly and its acquisition subsidiary will file with the United States Securities and Exchange Commission (the “SEC”) upon
commencement of the tender offer. A solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the
tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced,
Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED
LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE
DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING
THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter
of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of the Company at no
expense to them at Lilly’s website at investor.lilly.com and (once they become available) will be mailed to the stockholders of
the Company free of charge. Free copies of these materials and certain other offering documents will be made available by the Company
by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN 46268, Attention: Investor Relations, by email
at investors@pointbiopharma.com, or by directing requests for such materials to the information agent for the tender offer, which
will be named in the tender offer materials. The information contained in, or that can be accessed through, Lilly’s website is
not a part of, or incorporated by reference into, this communication. The tender offer materials (including the Offer to Purchase and
the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the
SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other
tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company file annual, quarterly, and current
reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly
and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward
Looking Statements
This
communication contains forward-looking statements related to the Company, Lilly and the proposed transaction that involve substantial
risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,”
“predict,” “project,” “seek,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue” and similar expressions. In this communication,
the Company’s forward-looking statements include statements about the parties’ ability to satisfy the conditions to the consummation
of the tender offer and the other conditions to the consummation of the proposed transaction; statements about the expected timetable
for completing the proposed transaction; the Company’s plans, objectives, expectations and intentions; the financial condition,
results of operations and business of the Company and Lilly; the ability to successfully commercialize the Company’s product candidates
and generate future revenues with respect to the Company’s product candidates; and the anticipated timing of the closing of the
proposed transaction.
Forward-looking
statements are subject to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or
results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and
uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among
other things: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s
stockholders will tender their shares in the tender offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the proposed transaction; the effects of the proposed transaction on relationships
with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and
Drug Administration approvals or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential
benefits of the proposed transaction; other business effects, including the effects of industry, economic or political conditions outside
of the companies’ control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk
Factors” in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports
on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by
the Company and the Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not
place undue reliance on these statements. All forward-looking statements are based on information currently available to the Company
and Lilly, and the Company and Lilly disclaim any obligation to update the information contained in this communication as new information
becomes available.
Exhibit 99.4
Media
Statement
The
combination of POINT’s team, infrastructure and capabilities with Lilly’s global resources and experience will accelerate
the discovery, development, and global access to the next generation of radiopharmaceuticals. We look forward to a future where patients
all over the world can benefit from the new cancer treatment options made possible by the joining of our two companies.
Please
direct questions about the specifics of the deal or integration plans to Lilly.
For
additional information, please see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma
Additional
Information and Where to Find It
The
tender offer described in this communication has not yet commenced. This communication is for informational purposes only and is neither
an offer to purchase nor a solicitation of an offer to sell any securities, nor is it a substitute for the tender offer materials that
Lilly and its acquisition subsidiary will file with the United States Securities and Exchange Commission (the “SEC”) upon
commencement of the tender offer. A solicitation and offer to buy outstanding shares of the Company will only be made pursuant to the
tender offer materials that Lilly and its acquisition subsidiary intend to file with the SEC. At the time the tender offer is commenced,
Lilly and its acquisition subsidiary will file tender offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation
Statement on Schedule 14D-9 with the SEC with respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED
LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT
INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE
DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL
CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING
THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials (including the Offer to Purchase and the related Letter
of Transmittal), as well as the Solicitation/Recommendation Statement, will be made available to all stockholders of the Company at no
expense to them at Lilly’s website at investor.lilly.com and (once they become available) will be mailed to the stockholders of
the Company free of charge. Free copies of these materials and certain other offering documents will be made available by the Company
by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN 46268, Attention: Investor Relations, by email
at investors@pointbiopharma.com, or by directing requests for such materials to the information agent for the tender offer, which
will be named in the tender offer materials. The information contained in, or that can be accessed through, Lilly’s website is
not a part of, or incorporated by reference into, this communication. The tender offer materials (including the Offer to Purchase and
the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made available for free on the
SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal and certain other
tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company file annual, quarterly, and current
reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed by Lilly
and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward
Looking Statements
This
communication contains forward-looking statements related to the Company, Lilly and the proposed transaction that involve substantial
risks and uncertainties. Forward-looking statements include any statements containing the words “anticipate,” “believe,”
“estimate,” “expect,” “intend”, “goal,” “may”, “might,” “plan,”
“predict,” “project,” “seek,” “target,” “potential,” “will,”
“would,” “could,” “should,” “continue” and similar expressions. In this communication,
the Company’s forward-looking statements include statements about the parties’ ability to satisfy the conditions to the consummation
of the tender offer and the other conditions to the consummation of the proposed transaction; statements about the expected timetable
for completing the proposed transaction; the Company’s plans, objectives, expectations and intentions; the financial condition,
results of operations and business of the Company and Lilly; the ability to successfully commercialize the Company’s product candidates
and generate future revenues with respect to the Company’s product candidates; and the anticipated timing of the closing of the
proposed transaction.
Forward-looking
statements are subject to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or
results to differ materially from those indicated in any such statements due to a number of risks and uncertainties. Those risks and
uncertainties that could cause the actual results to differ from expectations contemplated by forward-looking statements include, among
other things: uncertainties as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s
stockholders will tender their shares in the tender offer; the possibility that competing offers will be made; the possibility that various
closing conditions for the proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay
or refuse to grant approval for the consummation of the proposed transaction; the effects of the proposed transaction on relationships
with employees, other business partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and
Drug Administration approvals or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential
benefits of the proposed transaction; other business effects, including the effects of industry, economic or political conditions outside
of the companies’ control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk
Factors” in the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports
on Form 8-K, quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by
the Company and the Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not
place undue reliance on these statements. All forward-looking statements are based on information currently available to the Company
and Lilly, and the Company and Lilly disclaim any obligation to update the information contained in this communication as new information
becomes available.
Exhibit 99.5
Form of Letter for Upcoming Meetings
Dear [NAME],
It was announced that POINT Biopharma
Global Inc. (“POINT”) has agreed to be acquired by Lilly.
Due to the announcement, POINT’s
management will not be participating at [upcoming investor event] and must cancel their meeting with you.
For any questions on the proposed acquisition,
please reference the press release and related SEC filings.
Best, XX
For additional information, please
see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma.
Additional Information and Where
to Find It
The tender offer described in this communication
has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of
an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will
file with the United States Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. A solicitation
and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Lilly and its acquisition
subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender
offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER
OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS
AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER
OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation
Statement, will be made available to all stockholders of the Company at no expense to them at Lilly’s website at investor.lilly.com
and (once they become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and
certain other offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to
the information agent for the tender offer, which will be named in the tender offer materials. The information contained in, or that
can be accessed through, Lilly’s website is not a part of, or incorporated by reference into, this communication. The tender offer
materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement,
will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related
Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company
file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements
or other information filed by Lilly and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This communication contains forward-looking
statements related to the Company, Lilly and the proposed transaction that involve substantial risks and uncertainties. Forward-looking
statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,”
“seek,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue” and similar expressions. In this communication, the Company’s forward-looking statements include statements
about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation
of the proposed transaction; statements about the expected timetable for completing the proposed transaction; the Company’s plans,
objectives, expectations and intentions; the financial condition, results of operations and business of the Company and Lilly; the ability
to successfully commercialize the Company’s product candidates and generate future revenues with respect to the Company’s
product candidates; and the anticipated timing of the closing of the proposed transaction.
Forward-looking statements are subject
to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially
from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause
the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties
as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s stockholders will tender their
shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the
proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval
for the consummation of the proposed transaction; the effects of the proposed transaction on relationships with employees, other business
partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals
or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential benefits of the proposed
transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’
control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in
the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K,
quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by the Company and the
Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not place undue reliance
on these statements. All forward-looking statements are based on information currently available to the Company and Lilly, and the Company
and Lilly disclaim any obligation to update the information contained in this communication as new information becomes available.
Exhibit 99.6
Form of Letter to Business Partners
Dear [NAME],
Earlier today, it was announced
that POINT Biopharma Global Inc. (“POINT”) has agreed to be acquired by Lilly. The transaction is expected to close by the
end of this year.
We are excited to see our pipeline benefit
from the resources, expertise and global reach of Lilly’s organization. As a valued supplier / partner of POINT, we wanted to reach
out and confirm that for the time being our work with you will continue as usual. We will be in touch with further information as details
about the integration are finalized. We appreciate your continued partnership.
If you have any immediate questions,
please do not hesitate to reach out to me/XXX at XXX.
Best, XX
For additional information, please
see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma
Additional Information and Where
to Find It
The tender offer described in this communication
has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of
an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will
file with the United States Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. A solicitation
and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Lilly and its acquisition
subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender
offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER
OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS
AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER
OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation
Statement, will be made available to all stockholders of the Company at no expense to them at Lilly’s website at investor.lilly.com
and (once they become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and
certain other offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to
the information agent for the tender offer, which will be named in the tender offer materials. The information contained in, or that
can be accessed through, Lilly’s website is not a part of, or incorporated by reference into, this communication. The tender offer
materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement,
will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related
Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company
file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements
or other information filed by Lilly and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This communication contains forward-looking
statements related to the Company, Lilly and the proposed transaction that involve substantial risks and uncertainties. Forward-looking
statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,”
“seek,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue” and similar expressions. In this communication, the Company’s forward-looking statements include statements
about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation
of the proposed transaction; statements about the expected timetable for completing the proposed transaction; the Company’s plans,
objectives, expectations and intentions; the financial condition, results of operations and business of the Company and Lilly; the ability
to successfully commercialize the Company’s product candidates and generate future revenues with respect to the Company’s
product candidates; and the anticipated timing of the closing of the proposed transaction.
Forward-looking statements are subject
to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially
from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause
the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties
as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s stockholders will tender their
shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the
proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval
for the consummation of the proposed transaction; the effects of the proposed transaction on relationships with employees, other business
partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals
or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential benefits of the proposed
transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’
control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in
the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K,
quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by the Company and the
Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not place undue reliance
on these statements. All forward-looking statements are based on information currently available to the Company and Lilly, and the Company
and Lilly disclaim any obligation to update the information contained in this communication as new information becomes available.
Exhibit 99.7
Form of Letter to Key Investigators
Dear [NAME],
Earlier today, it was announced
that POINT Biopharma Global Inc. (“POINT”) has agreed to be acquired by Lilly. We are excited to see our pipeline benefit
from Lilly’s commitment to oncology, its rich history of innovation and its deep commitment to serving the needs of patients.
As a key partner on our clinical trials,
we wanted to reach out and confirm that all of our ongoing studies will continue to run as usual. The transaction is expected to close
by the end of this year, and there will be no changes for the study sites or clinical trial patients between now and then. We will be
in touch with further information as details about the integration are finalized.
In the meantime, if you have any questions,
please feel free to reach out to me/XXX at XXX. We appreciate your continued commitment to this study.
Best, XX
For additional information, please
see announcement press release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma
Additional Information and Where
to Find It
The tender offer described in this communication
has not yet commenced. This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of
an offer to sell any securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will
file with the United States Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. A solicitation
and offer to buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Lilly and its acquisition
subsidiary intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender
offer materials on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with
respect to the tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER
OFFER DOCUMENTS) AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND
THE PARTIES THERETO. INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE
(AND EACH AS IT MAY BE AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS
AND STOCKHOLDERS OF THE COMPANY SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER
OFFER. The tender offer materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation
Statement, will be made available to all stockholders of the Company at no expense to them at Lilly’s website at investor.lilly.com
and (once they become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and
certain other offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to
the information agent for the tender offer, which will be named in the tender offer materials. The information contained in, or that
can be accessed through, Lilly’s website is not a part of, or incorporated by reference into, this communication. The tender offer
materials (including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement,
will also be made available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related
Letter of Transmittal and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company
file annual, quarterly, and current reports, proxy statements and other information with the SEC. You may read any reports, statements
or other information filed by Lilly and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This communication contains forward-looking
statements related to the Company, Lilly and the proposed transaction that involve substantial risks and uncertainties. Forward-looking
statements include any statements containing the words “anticipate,” “believe,” “estimate,” “expect,”
“intend”, “goal,” “may”, “might,” “plan,” “predict,” “project,”
“seek,” “target,” “potential,” “will,” “would,” “could,” “should,”
“continue” and similar expressions. In this communication, the Company’s forward-looking statements include statements
about the parties’ ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation
of the proposed transaction; statements about the expected timetable for completing the proposed transaction; the Company’s plans,
objectives, expectations and intentions; the financial condition, results of operations and business of the Company and Lilly; the ability
to successfully commercialize the Company’s product candidates and generate future revenues with respect to the Company’s
product candidates; and the anticipated timing of the closing of the proposed transaction.
Forward-looking statements are subject
to certain risks, uncertainties or other factors that are difficult to predict and could cause actual events or results to differ materially
from those indicated in any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause
the actual results to differ from expectations contemplated by forward-looking statements include, among other things: uncertainties
as to the timing of the tender offer and the merger; uncertainties as to how many of the Company’s stockholders will tender their
shares in the tender offer; the possibility that competing offers will be made; the possibility that various closing conditions for the
proposed transaction may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval
for the consummation of the proposed transaction; the effects of the proposed transaction on relationships with employees, other business
partners or governmental entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals
or actions, if any; the impact of competitive products and pricing; that Lilly may not realize the potential benefits of the proposed
transaction; other business effects, including the effects of industry, economic or political conditions outside of the companies’
control; transaction costs; actual or contingent liabilities; and other risks listed under the heading “Risk Factors” in
the Company’s periodic reports filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K,
quarterly reports on Form 10-Q, annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by the Company and the
Schedule TO and related tender offer documents to be filed by Lilly and its acquisition subsidiary. You should not place undue reliance
on these statements. All forward-looking statements are based on information currently available to the Company and Lilly, and the Company
and Lilly disclaim any obligation to update the information contained in this communication as new information becomes available.
Exhibit 99.8
The following social media posts were first used on October 3,
2023:
Point Biopharma Global Inc. (the “Company”) posted
the following message on LinkedIn
[URL: https://www.linkedin.com/feed/update/urn:li:activity:7114965022941872129/]:
“Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities
into Next-Generation Radioligand Therapies.
Read the full release as it contains important
information.” [URL:
https://www.prnewswire.com/news-releases/lilly-to-acquire-point-biopharma-to-expand-oncology-capabilities-into-next-generation-radioligand-therapies-301945243.html]
The Company posted the following message on Twitter and Facebook
[URL: https://twitter.com/PointBiopharma/status/1709165761292304586;
https://www.facebook.com/photo/?fbid=827324759179440&set=a.592760925969159]:
“Lilly to Acquire POINT Biopharma to Expand Oncology Capabilities
into Next-Generation Radioligand Therapies.
Read the full release at https://buff.ly/3rzT6Iz as it contains important
information.”
For additional information, please see announcement press
release https://www.pointbiopharma.com/press-releases/lilly-to-acquire-point-biopharma.
Additional Information and Where to Find It
The tender offer described in this communication has not yet commenced.
This communication is for informational purposes only and is neither an offer to purchase nor a solicitation of an offer to sell any
securities, nor is it a substitute for the tender offer materials that Lilly and its acquisition subsidiary will file with the United
States Securities and Exchange Commission (the “SEC”) upon commencement of the tender offer. A solicitation and offer to
buy outstanding shares of the Company will only be made pursuant to the tender offer materials that Lilly and its acquisition subsidiary
intend to file with the SEC. At the time the tender offer is commenced, Lilly and its acquisition subsidiary will file tender offer materials
on Schedule TO, and the Company will file a Solicitation/Recommendation Statement on Schedule 14D-9 with the SEC with respect to the
tender offer. THE OFFER MATERIALS (INCLUDING AN OFFER TO PURCHASE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS)
AND THE SOLICITATION/RECOMMENDATION STATEMENT WILL CONTAIN IMPORTANT INFORMATION ABOUT THE PROPOSED TRANSACTION AND THE PARTIES THERETO.
INVESTORS AND STOCKHOLDERS OF THE COMPANY ARE URGED TO READ THESE DOCUMENTS CAREFULLY WHEN THEY BECOME AVAILABLE (AND EACH AS IT MAY BE
AMENDED OR SUPPLEMENTED FROM TIME TO TIME) BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION THAT INVESTORS AND STOCKHOLDERS OF THE COMPANY
SHOULD CONSIDER BEFORE MAKING ANY DECISION REGARDING TENDERING THEIR SHARES OF COMMON STOCK IN THE TENDER OFFER. The tender offer materials
(including the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will be
made available to all stockholders of the Company at no expense to them at Lilly’s website at investor.lilly.com and (once they
become available) will be mailed to the stockholders of the Company free of charge. Free copies of these materials and certain other
offering documents will be made available by the Company by mail to POINT Biopharma Global Inc., 4850 West 78th Street, Indianapolis, IN
46268, Attention: Investor Relations, by email at investors@pointbiopharma.com, or by directing requests for such materials to the information
agent for the tender offer, which will be named in the tender offer materials. The information contained in, or that can be accessed
through, Lilly’s website is not a part of, or incorporated by reference into, this communication. The tender offer materials (including
the Offer to Purchase and the related Letter of Transmittal), as well as the Solicitation/Recommendation Statement, will also be made
available for free on the SEC’s website at www.sec.gov. In addition to the Offer to Purchase, the related Letter of Transmittal
and certain other tender offer documents, as well as the Solicitation/Recommendation Statement, Lilly and the Company file annual, quarterly,
and current reports, proxy statements and other information with the SEC. You may read any reports, statements or other information filed
by Lilly and the Company with the SEC for free on the SEC’s website at www.sec.gov.
Forward Looking Statements
This communication contains forward-looking statements related to
the Company, Lilly and the proposed transaction that involve substantial risks and uncertainties. Forward-looking statements include
any statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend”,
“goal,” “may”, “might,” “plan,” “predict,” “project,” “seek,”
“target,” “potential,” “will,” “would,” “could,” “should,” “continue”
and similar expressions. In this communication, the Company’s forward-looking statements include statements about the parties’
ability to satisfy the conditions to the consummation of the tender offer and the other conditions to the consummation of the proposed
transaction; statements about the expected timetable for completing the proposed transaction; the Company’s plans, objectives,
expectations and intentions; the financial condition, results of operations and business of the Company and Lilly; the ability to successfully
commercialize the Company’s product candidates and generate future revenues with respect to the Company’s product candidates;
and the anticipated timing of the closing of the proposed transaction.
Forward-looking statements are subject to certain risks, uncertainties
or other factors that are difficult to predict and could cause actual events or results to differ materially from those indicated in
any such statements due to a number of risks and uncertainties. Those risks and uncertainties that could cause the actual results to
differ from expectations contemplated by forward-looking statements include, among other things: uncertainties as to the timing of the
tender offer and the merger; uncertainties as to how many of the Company’s stockholders will tender their shares in the tender
offer; the possibility that competing offers will be made; the possibility that various closing conditions for the proposed transaction
may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation
of the proposed transaction; the effects of the proposed transaction on relationships with employees, other business partners or governmental
entities; the difficulty of predicting the timing or outcome of U.S. Food and Drug Administration approvals or actions, if any; the impact
of competitive products and pricing; that Lilly may not realize the potential benefits of the proposed transaction; other business effects,
including the effects of industry, economic or political conditions outside of the companies’ control; transaction costs; actual
or contingent liabilities; and other risks listed under the heading “Risk Factors” in the Company’s periodic reports
filed with the U.S. Securities and Exchange Commission, including current reports on Form 8-K, quarterly reports on Form 10-Q,
annual reports on Form 10-K, as well as the Schedule 14D-9 to be filed by the Company and the Schedule TO and related tender offer
documents to be filed by Lilly and its acquisition subsidiary. You should not place undue reliance on these statements. All forward-looking
statements are based on information currently available to the Company and Lilly, and the Company and Lilly disclaim any obligation to
update the information contained in this communication as new information becomes available.
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Apr 2024 bis Mai 2024
POINT Biopharma Global (NASDAQ:PNT)
Historical Stock Chart
Von Mai 2023 bis Mai 2024
